SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med. 1997; 337: 10291035.
  • 2
    Rutgeerts P, D'Haens G, Targan, S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology. 1999; 117: 761769.
  • 3
    Sands BF, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350: 876885.
  • 4
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002; 359: 15411549.
  • 5
    Rutgeerts P, Feagan BG, Lichenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004; 126: 402413.
  • 6
    Ollendorf DA, Massarotti E, Birbara C, et al. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm. 2005; 11: 383393.
  • 7
    Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord. 2004; 5: 36.
  • 8
    Berger A, Edelsberg J, Li TT, et al. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother. 2005; 39: 20212025.
  • 9
    Dassopoulos T, Nguyen GC, Bitton A, et al. Assessment of reliability and validity of IBD phenotyping within the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) IBD Genetics Consortium (IBDGC). Inflamm Bowel Dis. 2007; (in press).
  • 10
    Barzi F, Woodward M. Imputations of missing values in practice: results from imputations of serum cholesterol in 28 cohort studies. Am J Epidemiol. 2004; 160: 3445.
  • 11
    Parsi MA, Achkar JP, Richardson S, et al. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology. 2002; 123: 707713.
  • 12
    Vermeire S, Louis E, Carbonez A, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor) infliximab treatment in Crohn's disease. Am J Gastroenterol. 2002; 97: 23572363.
    Direct Link:
  • 13
    Fefferman DS, Lodhavia PJ, Alsahli M, et al. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm Bowel Dis. 2004; 10: 346351.
  • 14
    Kinney T, Rawlins M, Kozarek R, et al. Immunomodulators and “on demand” therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am J Gastroenterol. 2003; 98: 608612.
  • 15
    Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004; 2: 542553.
  • 16
    Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348: 601608.
  • 17
    Maser EA, Villela R, Silverberg M, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4: 12481254.